Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials

BACKGROUND: Alzheimer’s disease (AD) is a globally prevalent neurodegenerative condition, clinically characterized by progressive memory loss and gradual impairment of cognitive functions. Bapineuzumab is a fully humanized monoclonal antibody that binds to neurotoxic amyloid proteins in the brain, e...

Descripción completa

Detalles Bibliográficos
Autores principales: Abushouk, Abdelrahman Ibrahim, Elmaraezy, Ahmed, Aglan, Amro, Salama, Reham, Fouda, Samar, Fouda, Rana, AlSafadi, Ammar M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381133/
https://www.ncbi.nlm.nih.gov/pubmed/28376794
http://dx.doi.org/10.1186/s12883-017-0850-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381133/
https://www.ncbi.nlm.nih.gov/pubmed/28376794
http://dx.doi.org/10.1186/s12883-017-0850-1

Ejemplares similares